| Patent application number | Description | Published |
|---|
| 20080208311 | MULTIPLE INDEPENDENT NESTED STENT STRUCTURES AND METHODS FOR THEIR PREPARATION AND DEPLOYMENT - Blood vessels and other body lumens are stented using stent structures comprising a plurality of radially expansible rings where at least some of the rings comprise axially extending elements which interleave with axially extending elements on adjacent unconnected rings. The ring structures may be open cell structures or closed cell structures, and the axially extending elements will typically be formed as part of the open cell or closed cell structure. | 08-28-2008 |
| 20080234798 | APPARATUS AND METHODS FOR DELIVERY OF MULTIPLE DISTRIBUTED STENTS - Blood vessels and other body lumens are stented using multiple, discreet stent structures. Stent structures may be balloon expandable or self-expanding and are delivered by a delivery catheter which is repositioned to spaced-apart delivery sights. By coating the stents with particular biologically active substances, hyperplasia within and between the implanted stents can be inhibited. An exemplary delivery catheter comprises a catheter body having both a pusher rod for advancing the stents relative to a sheath and a reciprocatable delivery catheter for implanting the stents. | 09-25-2008 |
| 20080300590 | APPARATUS AND METHODS FOR MULTIPOLAR TISSUE WELDING - Apparatus, systems and methods of welding and coagulating tissue utilize a combination of monopolar and bipolar delivery of RF energy. This method is referred to as multipolar RF delivery and includes bringing a treatment apparatus having first and second electrodes to a treatment site. A first potential is applied to the first electrode and a second potential lower than the first is delivered to the second electrode. This results in current flow from the first electrode through the tissue to the second electrode and then through the tissue to a ground electrode. Current also flows from the first electrode through the tissue to the ground electrode and current may also flow from the first electrode through the tissue to the second electrode and return directly to the ground electrode. | 12-04-2008 |
| 20090104243 | Drug cores for sustained release of therapeutic agents - A solid drug core insert can be manufactured by injecting a liquid mixture comprising a therapeutic agent and a matrix precursor into a sheath body. The injection can be conducted at subambient temperatures. The mixture is cured to form a solid drug-matrix core. The therapeutic agent can be a liquid at about room temperature that forms a dispersion of droplets in the matrix material. A surface of the solid drug core is exposed, for example by cutting the tube, and the exposed surface of the solid drug core releases therapeutic quantities of the therapeutic agent when implanted into the patient. In some embodiments, the insert body inhibits release of the therapeutic agent, for example with a material substantially impermeable to the therapeutic agent, such that the therapeutic quantities are released through the exposed surface, thereby avoiding release of the therapeutic agent to non-target tissues. | 04-23-2009 |
| 20090312807 | METHODS AND APPARATUS FOR JOINT DISTRACTION - A method of treating a patient's joint having opposing joint surfaces includes providing an elongate member having a proximal end, a distal end and an expandable member near the distal end. The expandable member is positioned in the joint between the joint surfaces and expanded so as to separate the joint surfaces away from one another into a distracted position. The joint is manipulated while in the distracted position so that the joint is distracted and in flexion. A diagnostic or therapeutic procedure is then performed on the joint while maintaining the joint in the flexed and distracted position. | 12-17-2009 |
| 20090326439 | HIGH PRESSURE PRE-BURST FOR IMPROVED FLUID DELIVERY - A needle with multiple injection ports is used in connection with a high-pressure injection system to infuse a treatment solution into a treatment area below the dermis of the skin. The needle has multiple tines that extend outwardly from the injection ports while inside the treatment area to disrupt tissue in the treatment area and to create multiple pathways of infusion. The tines are withdrawn and the needle is partially withdrawn, and solution is injected from the needle into the treatment area at high pressure to infuse the tissue within the treatment area. The burst, infusion, and a treatment such as an energy or third solution may be interleaved and repeated multiple times. | 12-31-2009 |
| 20100036488 | Therapeutic device for pain management and vision - A therapeutic lens for the treatment of an epithelial defect comprises a layer of therapeutic material disposed over the stroma and/or Bowman's membrane to inhibit water flow from the tear liquid to the stroma and/or Bowman's membrane, such that corneal deturgescence can be restored to decrease corneal swelling and light scattering. The layer may cover and protect nerve fibers to decrease pain. The layer may comprise an index of refraction to inhibit light scatter from an anterior surface of the stroma and/or Bowman's membrane. The lens may comprise a curved anterior surface that provides functional vision for the patient when the epithelium regenerates. The layer of therapeutic material can be positioned on the eye in many ways, for example with a spray that is cured to adhere the layer to the exposed surface of the stroma and/or Bowman's membrane. | 02-11-2010 |
| 20100114309 | DRUG DELIVERY IMPLANTS FOR INHIBITION OF OPTICAL DEFECTS - An implant for use with an eye comprises an implantable structure and a therapeutic agent. The therapeutic agent is deliverable from the structure into the eye so as to therapeutically effect and/or stabilize a refractive property of the eye. In many embodiments, the refractive property of the eye may comprise at least one of myopia, hyperopia or astigmatism. The therapeutic agent can comprise a composition that therapeutically effects or stabilizes the refractive property of the eye. The therapeutic agent may comprise at least one of a mydriatic or a cycloplegic drug. For example, the therapeutic agent may include a cycloplegic that comprises at least one of atropine, cyclopentolate, succinylcholine, homatropine, scopolamine, or tropicamide. In many embodiments, a retention element can be attached to the structure to retain the structure along a natural tissue surface. | 05-06-2010 |
